CAS: 14155-86-3; 1-Bromo-5-Methoxypentane

相似化合物

34626-51-2 34626-51-2 50592-87-5

上下游产品

CAS号111-24-0 1,5-二溴戊烷 | CAS号124-41-4 甲醇钠 | CAS号4799-62-6 5-methoxypentan-1-ol | CAS号67-56-1 甲醇 | CAS号142-68-7 四氢吡喃 | CAS号88663-63-2 7-methoxyheptan... | CAS号58390-18-4 5-methoxy-N,N-d...

📜5-甲氧基-1-戊醇置于吡啶,三溴化磷体系中,化学反应生成1-溴-5-甲氧基戊烷
参考文献:The Preparation And Properties Of A Series Of Ethereal And Unsaturated Boranes
标题:The Preparation And Properties Of A Series Of Ethereal And Unsaturated Boranes
摘要:
Doi:10.1021/jo01107A010

专利信息

专利号:US-2024109924-A1
优先权日:2021-01-29
标 题 :Ip4-4,6 substituted derivative compounds
发明人：PÉREZ FERRER MARÃ?A DEL MAR; FERRER REYNÉS MIQUEL DAVID; BASSISSI MOHAMAD FIRAS; SALCEDO ROCA CAROLINA; SERRA COMAS CARME; CATENA RUIZ JUAN LORENZO; LLEBARIA SOLDEVILA AMADEU; ORTEGA CASTRO JOAQUÃ?N; PERELLÓ BESTARD JOAN
权利人:SANIFIT THERAPEUTICS S A
摘要:The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R1, R3, R7, and R11 are OPO32−, and R5 and R9 are selected from the group consisting of —O(Alkyl)nX, —O(Alkyl)yCy(Alkyl2)y-Z, —O(Alkyl)yA(Alkyl)y-Z′, and their thiophosphate analogs. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.

专利号:WO-2024023360-A1
优先权日:2022-07-29
标 题:Ip5 substituted compounds
发明人：SALCEDO ROCA CAROLINA; PÉREZ FERRER MARÃ?A DEL MAR; FERRER REYNÉS MIQUEL DAVID; BASSISSI MOHAMAD FIRAS; SERRA COMAS CARME; CATENA RUIZ JUAN LORENZO; LLEBARIA SOLDEVILA AMADEU; PERELLÓ BESTARD JOAN
权利人:SANIFIT THERAPEUTICS S A
摘要:The present invention provides IP5 substituted compounds of general formula I, their methods of synthesis and their uses. The IP5 substituted compounds of the invention are characterized for having -O(alkyl)nX, and -O(alkyl)yCy(alkyl)y'-Z chains in positions R1, R2, R4, and R5. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.